European Journal of Obstetrics & Gynecology and Reproductive Biology
Original ArticleCarcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer
Introduction
With an incidence of 1.5% of all malignant diseases of the uterus, mullerian mixed tumour is a rarity amongst the malignancies of the female genital tract. Primary locations may be the endometrium, the cervix and the ovary [1]. Many studies have been published on the carcinogenic potency of tamoxifen. In animal experiments, indications were found for a raised liver toxicity with secondary development of hepatocarcinomas. Development of endometrial hyperplasia, endometriosis, endometrial polyps and endometrial adenocarcinomas has been described 2, 3.
Section snippets
Case report
A 73-year-old patient was admitted to hospital with the putative diagnosis of an adnexal tumour. Seven years before, her right breast had been removed with axillary lymphnodectomy because of a breast carcinoma in tumour stage pT 2, pN 1biii, G2, M0, ER:+++, PR:++. An adjuvant tamoxifen therapy was started with 40 mg/day over 31 months. The patient was then switched to 30 mg tamoxifen per day. The gynecological investigation showed a tumour extending to the navel, which could not be delimited
Discussion
To our knowledge, three cases of heterologous mullerian mixed tumour under tamoxifen therapy have been reported. In this case, the simultaneous occurrence of endometriosis, endometrial intraepithelial carcinoma (EIC) and mullerian mixed tumour after tamoxifen treatment over many years is described. This coincidence has not been reported up to now, while the development of endometriosis under tamoxifen administration has already been mentioned 2, 3.
Tamoxifen is a synthetic nonsteroid triphenyl
References (7)
- et al.
Endometrial intraepithelial carcinoma: a distinctive lesion specially associated with tumours displaying serous differentiation
Hum Pathol
(1995) - et al.
Immunocytochemical study of epidermal growth factor receptor, transforming growth factor alpha and squamous differentiation in human endometrial carcinoma
Hum Pathol
(1994) - Silverberg SG, Kurman RJ. Mixed epithelial-nonepithelial tumours. In: Silverberg SG, Kurman RJ, editors. Atlas of...
Cited by (25)
Uterine Carcinosarcomas
2019, Seminars in Ultrasound, CT and MRICitation Excerpt :UCS is more common in black women and the median age at diagnosis is between 62 and 67 years old.2-4 Risk factors for developing UCS are the same as endometrial cancer and include advanced age, obesity, nulliparity, exogenous estrogen use, pelvic radiation, and tamoxifen.5-16 The relative risk of developing UCS after tamoxifen use is actually higher than risk of developing endometrial carcinoma (4.62-fold vs 2.07-fold risk increase).
Uterine carcinosarcomas associated with tamoxifen therapy. Report of two cases and review of the literature
2009, Journal de Gynecologie Obstetrique et Biologie de la ReproductionCarcinosarcoma of the uterus with melanocytic differentiation
2007, Pathology Research and PracticeMixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment
2003, Gynecologie Obstetrique et FertiliteEndometrial mixed müllerian tumor with heterologous elements following tamoxifen therapy for breast cancer: A case report and literature review
2002, European Journal of Obstetrics and Gynecology and Reproductive BiologyMalignant mixed mesodermal tumours: Biology and clinical aspects
2002, European Journal of Cancer